Clinical trials are now studying CAR T-cell therapy as an earlier treatment. For example, the CAR-PRISM study is assessing the use of CAR‑T soon after initial treatments or during high‑risk smoldering myeloma. 

Watch HealthTree's educational webinar: Should High-Risk Smoldering Myeloma Be Treated? Exploring CAR-T & Combination Therapy Options